Kazia Therapeutics (NASDAQ:KZIA) Shares Up 1.5%

Kazia Therapeutics Limited (NASDAQ:KZIA – Get Rating)’s share price shot up 1.5% during mid-day trading on Friday . The company traded as high as $1.35 and last traded at $1.35. 12,315 shares were traded during mid-day trading, a decline of 77% from the average session volume of 54,536 shares. The stock had previously closed at $1.33.

Analysts Set New Price Targets

Separately, HC Wainwright raised shares of Kazia Therapeutics from a “neutral” rating to a “buy” rating and set a $2.00 price target on the stock in a report on Tuesday, April 11th.

Kazia Therapeutics Price Performance

The business’s fifty day moving average price is $1.16 and its 200-day moving average price is $0.92.

Institutional Investors Weigh In On Kazia Therapeutics

A hedge fund recently bought a new stake in Kazia Therapeutics stock. OLD Mission Capital LLC bought a new stake in Kazia Therapeutics Limited (NASDAQ:KZIA – Get Rating) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 80,923 shares of the company’s stock, valued at approximately $89,000. OLD Mission Capital LLC owned approximately 0.58% of Kazia Therapeutics at the end of the most recent reporting period. 3.47% of the stock is owned by institutional investors.

About Kazia Therapeutics

(Get Rating)

Kazia Therapeutics Ltd. is a clinical stage oncology company It engages in the pharmaceutical research and development business. The company was founded by Graham Edmund Kelly in March 1994 and is headquartered in Sydney, Australia.